Cargando…

RIG-I and TLR-7/8 agonists as combination adjuvant shapes unique antibody and cellular vaccine responses to seasonal influenza vaccine

Influenza vaccine effectiveness could be improved by combination with an adjuvant with the potential to enhance the host-vaccine response both quantitatively and qualitatively. The goal of this study was to explore a RIG-I agonist (SDI-nanogel) and a TLR7/8 agonist (Imidazoquinoline (IMDQ)‐PEG‐Chol)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jangra, Sonia, Laghlali, Gabriel, Choi, Angela, Rathnasinghe, Raveen, Chen, Yong, Yildiz, Soner, Coughlan, Lynda, García-Sastre, Adolfo, De Geest, Bruno G., Schotsaert, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9679288/ https://www.ncbi.nlm.nih.gov/pubmed/36426358 http://dx.doi.org/10.3389/fimmu.2022.974016

Ejemplares similares

Sterilizing Immunity against SARS-CoV-2 Infection in Mice by a Single-Shot and Modified Imidazoquinoline TLR7/8 Agonist-Adjuvanted Recombinant Spike Protein Vaccine
por: Jangra, Sonia, et al.
Publicado: (2020)

Introduction of two prolines and removal of the polybasic cleavage site leads to optimal efficacy of a recombinant spike based SARS-CoV-2 vaccine in the mouse model
por: Amanat, Fatima, et al.
Publicado: (2020)

Introduction of Two Prolines and Removal of the Polybasic Cleavage Site Lead to Higher Efficacy of a Recombinant Spike-Based SARS-CoV-2 Vaccine in the Mouse Model
por: Amanat, Fatima, et al.
Publicado: (2021)

A multicomponent intranasal adjuvant drives durable humoral, cellular, and mucosal immune responses to SARS-CoV-2 in young and aged mice
por: Jangra, Sonia, et al.
Publicado: (2023)

Prophylactic protection against respiratory viruses conferred by a prototype live attenuated influenza virus vaccine.
por: Rathnasinghe, Raveen, et al.
Publicado: (2021)

The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera.
por: Jangra, Sonia, et al.
Publicado: (2021)

The virucidal effects of 405 nm visible light on SARS-CoV-2 and influenza A virus
por: Rathnasinghe, Raveen, et al.
Publicado: (2021)

Interferon mediated prophylactic protection against respiratory viruses conferred by a prototype live attenuated influenza virus vaccine lacking non-structural protein 1
por: Rathnasinghe, Raveen, et al.
Publicado: (2021)

Multicomponent intranasal adjuvant for mucosal and durable systemic SARS-CoV-2 immunity in young and aged mice
por: Jangra, Sonia, et al.
Publicado: (2023)

Influenza breakthrough infection in vaccinated mice is characterized by non-pathological lung eosinophilia
por: Chang, Lauren A., et al.
Publicado: (2023)

Comparison of Transgenic and Adenovirus hACE2 Mouse Models for SARS-CoV-2 Infection
por: Rathnasinghe, Raveen, et al.
Publicado: (2020)

Comparison of transgenic and adenovirus hACE2 mouse models for SARS-CoV-2 infection
por: Rathnasinghe, Raveen, et al.
Publicado: (2020)

SARS-CoV-2 spike E484K mutation reduces antibody neutralisation
por: Jangra, Sonia, et al.
Publicado: (2021)

A Combination Adjuvant for the Induction of Potent Antiviral Immune Responses for a Recombinant SARS-CoV-2 Protein Vaccine
por: Jangra, Sonia, et al.
Publicado: (2021)

The N501Y mutation in SARS-CoV-2 spike leads to morbidity in obese and aged mice and is neutralized by convalescent and post-vaccination human sera
por: Rathnasinghe, Raveen, et al.
Publicado: (2021)

Replication-Competent ΔNS1 Influenza A Viruses Expressing Reporter Genes
por: Nogales, Aitor, et al.
Publicado: (2021)

TLR Agonists as Vaccine Adjuvants Targeting Cancer and Infectious Diseases
por: Luchner, Marina, et al.
Publicado: (2021)

Influenza Vaccines: A Moving Interdisciplinary Field
por: Schotsaert, Michael, et al.
Publicado: (2014)

A novel defined TLR3 agonist as an effective vaccine adjuvant
por: Ko, Kwang Hyun, et al.
Publicado: (2023)

Host immune response–inspired development of the influenza vaccine
por: Choi, Angela, et al.
Publicado: (2020)

BBIQ, a pure TLR7 agonist, is an effective influenza vaccine adjuvant
por: Kaushik, Deepender, et al.
Publicado: (2020)

Combination of STING and TLR 7/8 Agonists as Vaccine Adjuvants for Cancer Immunotherapy
por: Bhatnagar, Shubhmita, et al.
Publicado: (2022)

Nanoparticle-delivered TLR4 and RIG-I agonists enhance immune response to SARS-CoV-2 subunit vaccine
por: Atalis, Alexandra, et al.
Publicado: (2022)

Scalable, effective, and rapid decontamination of SARS-CoV-2 contaminated N95 respirators using germicidal ultraviolet C (UVC) irradiation device
por: Rathnasinghe, Raveen, et al.
Publicado: (2021)

Enhancing the protection of influenza virus vaccines with BECC TLR4 adjuvant in aged mice
por: Haupt, Robert, et al.
Publicado: (2023)

Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A
por: White, Kris M., et al.
Publicado: (2021)

The TLR7 agonist imiquimod as an adjuvant for radiotherapy-elicited in situ vaccination against breast cancer
por: Demaria, Sandra, et al.
Publicado: (2013)

Molecular Signatures of a TLR4 Agonist-Adjuvanted HIV-1 Vaccine Candidate in Humans
por: Anderson, Jenna, et al.
Publicado: (2018)

TLR3 and TLR9 Agonists Improve Postexposure Vaccination Efficacy of Live Smallpox Vaccines
por: Israely, Tomer, et al.
Publicado: (2014)

TIV Vaccination Modulates Host Responses to Influenza Virus Infection that Correlate with Protection against Bacterial Superinfection
por: Choi, Angela, et al.
Publicado: (2019)

A Dual TLR Agonist Adjuvant Enhances the Immunogenicity and Protective Efficacy of the Tuberculosis Vaccine Antigen ID93
por: Orr, Mark T., et al.
Publicado: (2014)

New Glucosamine-Based TLR4 Agonists: Design, Synthesis, Mechanism of Action, and In Vivo Activity as Vaccine Adjuvants
por: Romerio, Alessio, et al.
Publicado: (2023)

OMV Vaccines and the Role of TLR Agonists in Immune Response
por: Mancini, Francesca, et al.
Publicado: (2020)

A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses
por: Sun, Weina, et al.
Publicado: (2021)

Non-sterilizing, Infection-Permissive Vaccination With Inactivated Influenza Virus Vaccine Reshapes Subsequent Virus Infection-Induced Protective Heterosubtypic Immunity From Cellular to Humoral Cross-Reactive Immune Responses
por: Choi, Angela, et al.
Publicado: (2020)

An Overview of Recent Insights into the Response of TLR to SARS-CoV-2 Infection and the Potential of TLR Agonists as SARS-CoV-2 Vaccine Adjuvants
por: Kayesh, Mohammad Enamul Hoque, et al.
Publicado: (2021)

The TLR4 Agonist Vaccine Adjuvant, GLA-SE, Requires Canonical and Atypical Mechanisms of Action for T(H)1 Induction
por: Cauwelaert, Natasha Dubois, et al.
Publicado: (2016)

A Formulated TLR7/8 Agonist is a Flexible, Highly Potent and Effective Adjuvant for Pandemic Influenza Vaccines
por: Van Hoeven, Neal, et al.
Publicado: (2017)

Alum Adjuvant and Built-in TLR7 Agonist Synergistically Enhance Anti-MUC1 Immune Responses for Cancer Vaccine
por: Zhou, Shi-Hao, et al.
Publicado: (2022)

Development of a TLR7/8 agonist adjuvant formulation to overcome early life hyporesponsiveness to DTaP vaccination
por: Dowling, David J., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_o5ufns3366dj47l7ilbett2fju